Dr. Davangere P. Devanand
Psychiatry (Geriatric Psychiatry Physician)
Medicare and federal program status
Opted out of Medicare from February 18, 2016 through February 18, 2028. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated October 21, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Geriatric Psychiatry Physician primary
NY license 160258
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $2,350 in total to this clinician.
| AbbVie Inc. | $1,350 |
|---|---|
| Acadia Pharmaceuticals Inc | $1,000 |
| Consulting Fee | $1,350 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,000 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Nov 17, 2025 | Consulting Fee | $1,350 |
| Acadia Pharmaceuticals Inc May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ACP-204 · ALZHEIMERS DISEASE PSYCHOSIS | $1,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $17,753 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05511363
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.